JP2023530785A - {2-[3-シクロヘキシル-3-(trans-4-プロポキシ-シクロヘキシル)-ウレイド]-チアゾール-5-イルスルファニル}-酢酸の結晶形およびその使用 - Google Patents

{2-[3-シクロヘキシル-3-(trans-4-プロポキシ-シクロヘキシル)-ウレイド]-チアゾール-5-イルスルファニル}-酢酸の結晶形およびその使用 Download PDF

Info

Publication number
JP2023530785A
JP2023530785A JP2023519156A JP2023519156A JP2023530785A JP 2023530785 A JP2023530785 A JP 2023530785A JP 2023519156 A JP2023519156 A JP 2023519156A JP 2023519156 A JP2023519156 A JP 2023519156A JP 2023530785 A JP2023530785 A JP 2023530785A
Authority
JP
Japan
Prior art keywords
crystalline form
peaks
xrpd pattern
theta
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023519156A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530785A5 (cg-RX-API-DMAC7.html
Inventor
テン,ジン
ツァオ,イージョン
Original Assignee
ブイティーブイ・セラピューティクス・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブイティーブイ・セラピューティクス・エルエルシー filed Critical ブイティーブイ・セラピューティクス・エルエルシー
Publication of JP2023530785A publication Critical patent/JP2023530785A/ja
Publication of JP2023530785A5 publication Critical patent/JP2023530785A5/ja
Priority to JP2026034319A priority Critical patent/JP2026108667A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
JP2023519156A 2020-06-08 2021-06-07 {2-[3-シクロヘキシル-3-(trans-4-プロポキシ-シクロヘキシル)-ウレイド]-チアゾール-5-イルスルファニル}-酢酸の結晶形およびその使用 Pending JP2023530785A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026034319A JP2026108667A (ja) 2020-06-08 2026-03-04 {2-[3-シクロヘキシル-3-(trans-4-プロポキシ-シクロヘキシル)-ウレイド]-チアゾール-5-イルスルファニル}-酢酸の結晶形およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063035994P 2020-06-08 2020-06-08
US63/035,994 2020-06-08
PCT/US2021/036082 WO2021252309A1 (en) 2020-06-08 2021-06-07 Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026034319A Division JP2026108667A (ja) 2020-06-08 2026-03-04 {2-[3-シクロヘキシル-3-(trans-4-プロポキシ-シクロヘキシル)-ウレイド]-チアゾール-5-イルスルファニル}-酢酸の結晶形およびその使用

Publications (2)

Publication Number Publication Date
JP2023530785A true JP2023530785A (ja) 2023-07-19
JP2023530785A5 JP2023530785A5 (cg-RX-API-DMAC7.html) 2024-06-13

Family

ID=78846441

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023519156A Pending JP2023530785A (ja) 2020-06-08 2021-06-07 {2-[3-シクロヘキシル-3-(trans-4-プロポキシ-シクロヘキシル)-ウレイド]-チアゾール-5-イルスルファニル}-酢酸の結晶形およびその使用
JP2026034319A Pending JP2026108667A (ja) 2020-06-08 2026-03-04 {2-[3-シクロヘキシル-3-(trans-4-プロポキシ-シクロヘキシル)-ウレイド]-チアゾール-5-イルスルファニル}-酢酸の結晶形およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026034319A Pending JP2026108667A (ja) 2020-06-08 2026-03-04 {2-[3-シクロヘキシル-3-(trans-4-プロポキシ-シクロヘキシル)-ウレイド]-チアゾール-5-イルスルファニル}-酢酸の結晶形およびその使用

Country Status (8)

Country Link
EP (1) EP4161639A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023530785A (cg-RX-API-DMAC7.html)
KR (1) KR20230048501A (cg-RX-API-DMAC7.html)
CN (2) CN116056760A (cg-RX-API-DMAC7.html)
AU (1) AU2021289591A1 (cg-RX-API-DMAC7.html)
CA (1) CA3181665A1 (cg-RX-API-DMAC7.html)
MX (2) MX2022015524A (cg-RX-API-DMAC7.html)
WO (1) WO2021252309A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3093025A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
US12479808B2 (en) 2020-06-08 2025-11-25 Vtv Therapeutics Llc Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016510741A (ja) * 2013-03-04 2016-04-11 ブイティーブイ・セラピューティクス・エルエルシー グルコキナーゼ活性化剤を含む固体組成物ならびにその同じものを作製および使用する方法
JP2016513625A (ja) * 2013-03-04 2016-05-16 ブイティーブイ・セラピューティクス・エルエルシー 安定なグルコキナーゼ活性化剤組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0506662B8 (pt) * 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
PT2576524T (pt) * 2010-05-26 2017-11-17 Vtv Therapeutics Llc Resumo
IN2014DN09554A (cg-RX-API-DMAC7.html) * 2012-05-17 2015-07-17 Transtech Pharma Llc
DK3556354T3 (da) * 2016-12-15 2025-08-04 Hua Medicine Shanghai Ltd Oral fremstilling af en glucokinaseaktivator og fremgangsmåde til fremstilling deraf

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016510741A (ja) * 2013-03-04 2016-04-11 ブイティーブイ・セラピューティクス・エルエルシー グルコキナーゼ活性化剤を含む固体組成物ならびにその同じものを作製および使用する方法
JP2016513625A (ja) * 2013-03-04 2016-05-16 ブイティーブイ・セラピューティクス・エルエルシー 安定なグルコキナーゼ活性化剤組成物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BASTIN,R.J. ET AL: "Salt selection and optimization procedures for pharmaceutical new chemical entities", ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 4, JPN6009059058, 2000, pages 427 - 435, ISSN: 0005722934 *
寺田勝英: "熱分析の医薬品開発への応用", NETSU SOKUTEI, vol. 38, no. 2, JPN6023001927, 2011, pages 46 - 53, ISSN: 0005722932 *
山野光久: "医薬品のプロセス研究における結晶多形現象への取り組み", 有機合成化学協会, vol. 65, no. 9, JPN6023001929, 2007, pages 907 - 913, ISSN: 0005722933 *

Also Published As

Publication number Publication date
MX2026000786A (es) 2026-03-02
CN116056760A (zh) 2023-05-02
JP2026108667A (ja) 2026-06-30
US20230219910A1 (en) 2023-07-13
EP4161639A4 (en) 2024-01-17
AU2021289591A1 (en) 2023-01-19
MX2022015524A (es) 2023-03-22
CA3181665A1 (en) 2021-12-16
WO2021252309A1 (en) 2021-12-16
EP4161639A1 (en) 2023-04-12
CN121202809A (zh) 2025-12-26
KR20230048501A (ko) 2023-04-11

Similar Documents

Publication Publication Date Title
AU2023202085B2 (en) Polymorphic forms of RAD1901-2HCL
JP6809681B2 (ja) 2−ヒドロキシ−6−((2−(1−イソプロピル−1h−ピラゾール−5−イル)ピリジン−3−イル)メトキシ)ベンズアルデヒドの遊離塩基の結晶多形
EP4010322B1 (en) Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof
AU2017373784B2 (en) Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
AU2021289591A1 (en) Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof
TW202128627A (zh) 選擇性鉀通道調節劑之固態晶型
US12479808B2 (en) Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof
JP2016512516A (ja) キナゾリン誘導体の固体形態およびbraf阻害剤としてのその使用
CN113754596A (zh) 一种吉非替尼的共晶体
RU2710230C1 (ru) Аминный сольват ингибитора натрий-глюкозного котранспортера и способ его получения и его применение
CN114075169B (zh) 奥希替尼药用共晶体及其制备方法
HK40131995A (en) Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and uses thereof
JP2025525475A (ja) N-[4-(4-[[2-(ジメチルアミノ)エチル]アミノ]-3-メチル-1H-ピラゾロ[3,4-d]ピリミジン-6-イル)-2-フルオロフェニル]-2,5-ジフルオロベンゼンスルホンアミドの塩及びそれらの結晶形態
US20250304635A1 (en) Birinapant polymorph h
US20230147121A1 (en) Compositions of solid forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide
HK40119275A (en) Co-crystal forms of a novobiocin analog and proline
HK40079891A (en) Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists
HK40120019A (en) Solid state crystalline forms of a selective potassium channel modulator
HK40079890A (en) Compositions and methods related to picolinylpiperidine 5-ht1f agonists
EA052101B1 (ru) Ингибирующее p2x3 соединение, его соль, его полиморф и его применение
CN112823161B (zh) 共晶体及其用途
HK40074778A (en) Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof
HK40074778B (en) Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof
EP2280980A1 (en) Crystalline form of n-[[4-fluoro-2-(5-methyl-1h-1,2,4-triazol-1-yl)phenyl]methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide, sodium salt monohydrate
EA046754B1 (ru) Композиция, связанная с пиридиноилпиперидиновыми агонистами 5-ht1f

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240605

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250716

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251104